An ASPIRE-BioNEST Startup ReaGene Innovations was presented best Research Award at the Advances in Molecular Diagnostics and Precision Medicine International Conference in Chennai from 15 – 17 September 2022.
The award was in recognition of their work on designing 3D bioprinted human models of COVID-19 and Type 2 Diabetes which the Company used to launch therapeutics in less than 2 years. 3D bioprinting is a cutting-edge technology which allows scientists to create human-like organs for discovery and development of drugs against human diseases. The presentation was made by the Companies’ young scientific team of Arpitha Reddy R.N, Sanjana Battula and Saranya K with contribution from Kranti Meher.
Dr. Uday Saxena, Co-Founder and CEO of Reagene Innovations said that the use of 3D bioprinting of human like organs and disease systems can save the pharma industry time, several millions of dollars and increase likelihood of success in launching new products. Dr. Subrahmanyam Vangala, Co-Founder of Reagene Innovations, added that this is breakthrough technology which was much needed in an industry where failure rates are high. Dr. Satish Chandran, CEO of Lay Sciences, USA, the Company’s business partner, said that bringing new products rapidly to the patient’s using 3D technologies is the beginning of a new paradigm in the healthcare industry.
ReaGene Innovations and its Science and Business partners, Lay Sciences USA, Prodigy Bio, USA and Kyntox Bio, Bengaluru plan to collaborate extensively to bring forward several new product launches using similar innovative and proprietary discovery platforms.